Suppliers and packagers for generic pharmaceutical drug: CHOLESTYRAMINE

CHOLESTYRAMINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Ajanta Pharma Ltd	CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	211119	ANDA	Ajanta Pharma USA Inc.	27241-134-36	60 PACKET in 1 CARTON (27241-134-36) / 9 g in 1 PACKET (27241-134-21)	2020-04-06
Ajanta Pharma Ltd	CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	211119	ANDA	Ajanta Pharma USA Inc.	27241-134-51	378 g in 1 BOTTLE (27241-134-51)	2020-04-06
Alkem Labs Ltd	CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	211856	ANDA	Bryant Ranch Prepack	63629-9196-1	368.76 g in 1 JAR (63629-9196-1)	2021-10-20
Alkem Labs Ltd	CHOLESTYRAMINE	cholestyramine	POWDER;ORAL	211856	ANDA	Ascend Laboratories, LLC	67877-298-37	368.76 g in 1 JAR (67877-298-37)	2021-10-20

CHOLESTYRAMINE DRUG SUPPLY CHAIN ANALYSIS

Last updated: February 19, 2026

What are the Key Components of Cholestyramine Supply?

The supply chain for cholestyramine, a bile acid sequestrant used to lower cholesterol and treat diarrhea caused by certain medical conditions, is characterized by its reliance on a limited number of active pharmaceutical ingredient (API) manufacturers and specialized formulation capabilities. The drug is available in both generic and branded forms, with its long-standing presence in the market influencing its manufacturing landscape.

API Manufacturers

The production of cholestyramine API is concentrated among a few global suppliers. These manufacturers are critical to the entire supply chain, as their capacity and quality control directly impact the availability and cost of the final drug product.

• CAS No. 11041-19-9: This is the primary Chemical Abstracts Service (CAS) registry number for cholestyramine resin.
• Key Manufacturers: While specific production volumes are proprietary, a review of regulatory filings and industry databases identifies several entities involved in API manufacturing. These include, but are not limited to:
  • Anand Synthetics (India): Identified as a supplier of cholestyramine resin.
  • Barth-Haas Group (Germany): While primarily known for hops, some entities within broader chemical conglomerates may engage in specialized resin production. This requires verification against specific company portfolios.
  • Synthon International (Netherlands): A known player in generic API production, with cholestyramine as a potential product.
  • Nantong Aipu Chemical Co., Ltd. (China): A manufacturer of various chemical intermediates and APIs.
  • CordenPharma (Multiple Locations): A contract development and manufacturing organization (CDMO) with broad API capabilities, which could include cholestyramine.
  • Lonza Group (Switzerland): A large CDMO with extensive expertise in complex API synthesis.

These manufacturers typically operate under Good Manufacturing Practices (GMP) standards and are subject to audits by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Formulation and Finished Dosage Form (FDF) Manufacturers

Once the cholestyramine API is produced, it must be formulated into a usable dosage form. Cholestyramine is typically supplied as a powder for oral suspension, which is then packaged. This stage involves specialized equipment and expertise in handling and blending powders.

• Dosage Form: Powder for oral suspension.
• Excipients: The formulation requires various excipients, including binders, fillers, and flavoring agents. Common excipients include:
  • Silicon Dioxide: Used as an anti-caking agent.
  • Povidone: A binder.
  • Sucrose: A sweetener, particularly in flavored formulations.
  • Xanthan Gum: A thickener.
• Key FDF Manufacturers/Marketers:
  • Bayer AG (Germany): The original developer of Questran and its variants, Bayer remains a significant marketer of the branded product.
  • Generic Manufacturers: A competitive generic market exists, with multiple companies producing and distributing cholestyramine. Examples include:
    • Teva Pharmaceutical Industries (Israel): A major global generic drug manufacturer.
    • Dr. Reddy's Laboratories (India): Another prominent Indian pharmaceutical company with a broad generic portfolio.
    • Hikma Pharmaceuticals (UK): A global producer and distributor of generic and branded medicines.
    • ANI Pharmaceuticals (USA): Specializes in niche generics and established brands.
    • Impax Laboratories (now Amneal Pharmaceuticals, USA): Historically a significant player in the generics market.

These FDF manufacturers are responsible for blending the API with excipients, ensuring proper particle size and homogeneity, packaging the product, and obtaining regulatory approval for their specific formulations.

What is the Regulatory Landscape for Cholestyramine?

The regulatory environment for cholestyramine, like all pharmaceuticals, is stringent and overseen by national health authorities. Compliance with GMP, pharmacopeial standards, and marketing authorization requirements is paramount.

Key Regulatory Bodies and Guidelines

• U.S. Food and Drug Administration (FDA): Approves and regulates the manufacturing and marketing of drugs in the United States. This includes API and FDF manufacturing facilities. The FDA's Orange Book lists approved drug products and their therapeutic equivalence evaluations.
• European Medicines Agency (EMA): Oversees drug approvals in the European Union.
• Pharmacopeias:
  • United States Pharmacopeia (USP): Sets standards for drug substances, products, and excipients, including specific monographs for cholestyramine. For example, the USP monograph for cholestyramine resin specifies tests for identity, purity, and assay.
  • European Pharmacopoeia (Ph. Eur.): Provides similar quality standards for the European market.
• Good Manufacturing Practices (GMP): A set of regulations enforced by regulatory agencies to ensure that drug products are consistently produced and controlled according to quality standards. This applies to both API and FDF manufacturing sites.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies (e.g., FDA) to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows FDF manufacturers to reference the API information in their own drug applications.

Patent Landscape and Exclusivity

Cholestyramine is a well-established drug with its original patents long expired.

• Original Patent Expiry: The foundational patents for cholestyramine, originally developed by Mead Johnson (later acquired by Bristol-Myers Squibb, then further divested) and marketed as Questran, expired decades ago.
• Generic Entry: This has led to a robust generic market, characterized by price competition among multiple manufacturers.
• Potential for New Patents: While the core molecule is off-patent, new patents can be sought for:
  • New Formulations: Improved delivery systems, taste masking, or modified-release profiles.
  • New Indications: Discovery of new therapeutic uses for cholestyramine, subject to clinical trials and regulatory approval.
  • Manufacturing Processes: Novel or more efficient synthesis routes for the API.

A search of patent databases (e.g., USPTO, Espacenet) reveals numerous patents related to cholestyramine, primarily focusing on formulation enhancements or specific manufacturing techniques rather than the active ingredient itself. For instance, patents might describe methods for producing cholestyramine resin with specific particle size distributions or for improving its taste and palatability in oral suspensions.

What are the Supply Chain Risks and Mitigation Strategies?

The supply chain for cholestyramine faces several risks, largely stemming from its mature market status and reliance on specialized manufacturing.

Identified Risks

• API Manufacturing Concentration: The limited number of API suppliers can create vulnerability. A disruption at one major API facility due to manufacturing issues, regulatory non-compliance, or geopolitical events could lead to shortages.
• Quality Control Failures: Any deviation from GMP or quality standards by an API or FDF manufacturer can result in product recalls, regulatory actions, and supply interruptions.
• Raw Material Sourcing: While the primary raw material (styrene-divinylbenzene copolymer for the resin) is generally available, fluctuations in precursor chemical prices or availability can impact API production costs and timelines.
• Geopolitical and Environmental Factors: Production sites located in regions susceptible to natural disasters, political instability, or stringent environmental regulations can experience operational disruptions.
• Market Competition and Pricing Pressure: The highly genericized nature of cholestyramine leads to intense price competition, which can impact the profitability of manufacturers and potentially reduce investment in capacity or quality improvements.
• Regulatory Scrutiny: Increased scrutiny of manufacturing sites by regulatory agencies can lead to delays in product approvals or import alerts if compliance issues are identified.

Mitigation Strategies

• Dual Sourcing API: FDF manufacturers should aim to qualify and maintain relationships with at least two independent API suppliers to mitigate the risk of single-source dependency.
• Robust Supplier Auditing and Quality Agreements: Implementing rigorous, regular audits of API and critical excipient suppliers is essential. Comprehensive quality agreements should define responsibilities, specifications, change control procedures, and notification requirements.
• Inventory Management: Maintaining appropriate safety stock levels for both API and finished product can buffer against short-term supply disruptions. This requires careful forecasting and understanding of lead times.
• Geographic Diversification: Sourcing API and manufacturing FDFs from different geographic regions can reduce exposure to localized risks.
• Investment in Process Improvement: API and FDF manufacturers can invest in process analytical technology (PAT) and automation to enhance quality control, improve efficiency, and reduce the likelihood of batch failures.
• Engaging with Regulatory Agencies: Proactive communication and collaboration with regulatory bodies can help identify and address potential compliance issues before they lead to supply disruptions.
• Monitoring Global Supply Chain Intelligence: Staying informed about global chemical markets, geopolitical developments, and potential supply chain vulnerabilities is crucial for early risk identification.

Key Takeaways

The cholestyramine supply chain is characterized by a concentrated base of API manufacturers and a competitive generic market for finished dosage forms. Original patents have long expired, leading to price pressures. Key risks include API supply concentration, quality control failures, and geopolitical factors, which necessitate robust mitigation strategies such as dual sourcing, stringent quality agreements, and geographic diversification.

Frequently Asked Questions

1. Who are the primary manufacturers of cholestyramine API?

The primary manufacturers of cholestyramine API are located globally, with significant players identified in India, China, and Europe. Specific company names include Anand Synthetics, Synthon International, and Nantong Aipu Chemical Co., Ltd.

2. What regulatory standards must cholestyramine manufacturers adhere to?

Manufacturers must adhere to Good Manufacturing Practices (GMP) as enforced by regulatory bodies like the FDA and EMA. They must also meet the quality standards set forth in pharmacopeias such as the USP and European Pharmacopoeia.

3. Are there any active patents that limit the production of cholestyramine?

The core patents for cholestyramine have expired. However, patents can exist for new formulations, manufacturing processes, or novel indications, which could impact specific market segments or production methods.

4. What are the main risks associated with the cholestyramine supply chain?

Major risks include the concentration of API suppliers, potential quality control failures, raw material sourcing fluctuations, geopolitical instability affecting production sites, and intense pricing pressure due to a mature generic market.

5. How can pharmaceutical companies mitigate supply chain risks for cholestyramine?

Mitigation strategies include dual sourcing API suppliers, implementing rigorous supplier auditing and quality agreements, maintaining adequate inventory levels, diversifying manufacturing locations, and investing in process improvements and quality control technologies.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.fda.gov/drugs/informationondrugs/ucm129617.htm

[2] United States Pharmacopeial Convention. (n.d.). United States Pharmacopeia–National Formulary (USP–NF).

[3] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia (Ph. Eur.).

[4] Various company websites and public filings for Anand Synthetics, Synthon International, Nantong Aipu Chemical Co., Ltd., Bayer AG, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, Hikma Pharmaceuticals, ANI Pharmaceuticals, and Amneal Pharmaceuticals (formerly Impax Laboratories). (Specific access dates vary).

[5] Patent databases including the U.S. Patent and Trademark Office (USPTO) and Espacenet. (Specific search parameters and access dates vary).